Tricia Carney
Payments from drug & device makers
Across 83 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$561
- AbbVie$182
- Novartis$150
- Lilly USA, LLC$134
- Biohaven Pharmaceuticals, Inc.$71
- Dexcom, Inc.$49
- plus $348 from 16 others
What the payments were for
- Consulting fees$17512%
- Food & beverage$1,32188%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $561 |
| AbbVie | 10 | $182 |
| Novartis | 8 | $150 |
| Lilly USA, LLC | 9 | $134 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Dexcom, Inc. | 2 | $49 |
| Pfizer | 3 | $42 |
| Grifols USA, LLC | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Exact Sciences | 2 | $29 |
| AstraZeneca | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| GSK | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Abbott | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
How this compares
$1,496 in reported general payments places this provider in the 80th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $23,296 |
| EliquisApixaban | 12 | $14,828 |
| TrulicityDulaglutide | 11 | $10,425 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $6,611 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $1,894 |
| Potassium Chloride | 68 | $1,324 |
| Duloxetine Hcl | 48 | $1,115 |
| Omeprazole | 48 | $783 |
| HumalogInsulin Lispro | 12 | $782 |
| Levothyroxine Sodium | 108 | $735 |
| Gabapentin | 69 | $629 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $610 |
| Pilocarpine Hcl | 13 | $530 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 34 | $488 |
| Famotidine | 22 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $15 | $23,29624 claims |
| PfizerEliquis | $42 | $14,82812 claims |
| Lilly USA, LLCTrulicity, Humalog | $134 | $11,20723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,579 family providers in Kansas.
Other family in Colby
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.